S. Padberg et al., One-year prophylactic treatment of euthyroid Hashimoto's thyroiditis patients with levothyroxine: Is there a benefit?, THYROID, 11(3), 2001, pp. 249-255
Studies in animal models of spontaneous Hashimoto's autoimmune thyroiditis
(HT) show that prophylactic treatment with levothyroxine (LT4) can reduce i
ncidence and degree of lymphocytic infiltration in HT. The aim of the prese
nt study was to clarify whether there is a benefit of prophylactic treatmen
t with LT4 in patients with euthyroid HT with respect to the progression of
the autoimmune process. Twenty-one patients with eu thyroid HT were checke
d for thyroid function (thyrotropin [TSH], free triiodothyronine [FT3], fre
e thyroxine [FT4]), thyroid volume, antibodies (thyroglobulin [Tg-Ab], thyr
oid peroxidase [TPO-Ab]), and lymphocyte subsets. Peripheral (PBL) and thyr
oid-derived lymphocytes (TL) were analyzed by triple color flow cytometry.
One-half of the patients with euthyroid HT were treated with LT4 for 1 year
(n = 10). The other half (n = 11) were never treated with LT4. TL were obt
ained by fine-needle aspiration biopsy (FNAB). Thirteen healthy subjects (C
) without medical history of thyroid disease serc ed as controls concerning
PBL, and patients with nontoxic nodular goiter (NG; n = 10) served as cont
rols concerning TL. Thyroid-derived TT-helper cells were found more frequen
tly in euthyroid patients with HT compared to patients with NG (p < 0.01).
After 1 year of therapy with LT4, TPO-Abs and B lymphocytes decreased signi
ficantly only in the treated group of euthyroid patients with HT (p < 0.05)
. In contrast, TPO-Abs levels did not change or even increased in untreated
euthyroid patients with HT. Thyroid volume did not differ before and after
therapy. Prophylactic treatment of euthyroid patients with HT reduced both
serological and cellular markers of autoimmune thyroiditis. Therefore, pro
phylactic LTB4 treatment might be useful to stop the progression or even ma
nifestation of the disease. However, the long-term clinical benefit of prop
hylactic LT4 therapy in euthyroid patients with HT is yet to be established
.